Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$549.31 USD

549.31
1,695,329

+24.03 (4.57%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $576.76 +27.45 (5.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 251)

Industry: Medical - Dental Supplies

Zacks News

Sweta Killa headshot

Top 5 Dividend Stocks to Cheer You Up This Holiday Season

We have selected five dividend growth stocks ¿¿¿ H&R Block (HRB), ParkerHannifin (PH), Archer-Daniels-Midland (ADM), Insperity (NSP) and McKesson (MCK) ¿¿¿ that could be compelling picks for your portfolio ahead of the holiday season.

Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?

Style Box ETF report for CLRG

Derek Lewis headshot

Invest Like Warren Buffett With These 3 Stocks

Many investors mimic Warren Buffett, closely following all of his moves. And with his track record of success, it's easy to see why.

Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?

Smart Beta ETF report for CLRG

McKesson (MCK) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

McKesson's (MCK) fiscal second-quarter 2023 results benefit from segmental growth.

McKesson (MCK) Lags Q2 Earnings Estimates

McKesson (MCK) delivered earnings and revenue surprises of -1.14% and 0.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Nalak Das headshot

Top 5 Stocks Set to Beat on Earnings After Markets Close

Five companies will report earnings results today after the closing bell. These are: CHK, MCK, ENLC, LTHM and ZI.

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

Cardinal Health's (CAH) first-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

Debanjana Dey headshot

MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More

MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.

Why Earnings Season Could Be Great for McKesson (MCK)

McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks.com featured highlights include Heritage-Crystal Clean, Cadence Design Systems, McKesson and Schlumberger

Heritage-Crystal Clean, Cadence Design Systems, McKesson and Schlumberger are part of the Zacks Screen of the Week article.

AmerisourceBergen (ABC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AmerisourceBergen (ABC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sumit Singh headshot

Pick These 4 Stocks With Excellent Interest Coverage Ratio

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Heritage-Crystal (HCCI), Cadence (CDNS), McKesson (MCK) and Schlumberger (SLB) are capable of meeting financial obligations.

Merit Medical (MMSI) Q3 Earnings and Revenues Top Estimates

Merit Medical (MMSI) delivered earnings and revenue surprises of 20.75% and 5.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Q3 Earnings Miss, Operating Margin Up

Boston Scientific's (BSX) Q3 revenues reflect double-digit organic revenue growth across the majority of its businesses.

NextGen Healthcare (NXGN) Q2 Earnings Beat, FY23 View Up

NextGen's (NXGN) second-quarter fiscal 2023 results reflect strength in both its revenue sources.

Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?

Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.

Zacks Investment Ideas feature highlights: Elevance Health, McKesson and Humana

Elevance Health, McKesson and Humana are part of Zacks Investment Ideas article.

Derek Lewis headshot

3 Top-Ranked Medical Stocks Lapping the S&P 500

All three stocks are up double-digit percentages in 2022, leaving the S&P 500's performance in the dust. With the stocks carrying favorable near-term earnings outlooks, the run could easily continue.

CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?

CVS Health's (CVS) digital capabilities are anticipated to have enhanced consumer engagement across all CVS Health businesses in Q3.

McKesson (MCK) to Report Q2 Earnings: Is a Beat in the Cards?

McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.

McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

Ecolab's (ECL) third-quarter results are likely to reflect continued strength in its Global Industrial segment.